 Lee Newman
Concepts (513)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Occupational Health | 28 | 2022 | 165 | 12.300 |
Why?
| | Small Business | 14 | 2022 | 51 | 7.600 |
Why?
| | Saccharum | 14 | 2023 | 59 | 6.660 |
Why?
| | Berylliosis | 36 | 2018 | 177 | 5.810 |
Why?
| | Occupational Exposure | 30 | 2023 | 256 | 5.770 |
Why?
| | Farmers | 10 | 2022 | 42 | 5.600 |
Why?
| | Beryllium | 30 | 2018 | 146 | 4.850 |
Why?
| | Renal Insufficiency, Chronic | 12 | 2023 | 486 | 4.360 |
Why?
| | Occupational Injuries | 7 | 2023 | 46 | 3.750 |
Why?
| | Workplace | 25 | 2023 | 221 | 3.750 |
Why?
| | Agricultural Workers' Diseases | 5 | 2020 | 23 | 2.770 |
Why?
| | Health Promotion | 11 | 2021 | 675 | 2.680 |
Why?
| | Occupational Diseases | 9 | 2019 | 129 | 2.470 |
Why?
| | Heat Stress Disorders | 5 | 2023 | 40 | 2.430 |
Why?
| | Agriculture | 6 | 2020 | 71 | 2.290 |
Why?
| | Workers' Compensation | 4 | 2019 | 27 | 1.930 |
Why?
| | Hot Temperature | 7 | 2023 | 301 | 1.850 |
Why?
| | Organizational Culture | 5 | 2022 | 120 | 1.640 |
Why?
| | Leadership | 6 | 2022 | 291 | 1.640 |
Why?
| | Guatemala | 12 | 2021 | 267 | 1.630 |
Why?
| | Sarcoidosis | 13 | 2012 | 133 | 1.500 |
Why?
| | Glomerular Filtration Rate | 5 | 2021 | 605 | 1.450 |
Why?
| | Safety Management | 6 | 2021 | 106 | 1.420 |
Why?
| | Kidney | 6 | 2021 | 1181 | 1.300 |
Why?
| | Humans | 132 | 2023 | 114077 | 1.250 |
Why?
| | Creatinine | 6 | 2023 | 424 | 1.220 |
Why?
| | Absenteeism | 2 | 2018 | 40 | 1.140 |
Why?
| | Adult | 56 | 2021 | 30394 | 1.120 |
Why?
| | Chronic Disease | 25 | 2018 | 1579 | 1.100 |
Why?
| | Lymphocytes | 4 | 2018 | 327 | 1.090 |
Why?
| | Health Behavior | 5 | 2022 | 701 | 1.090 |
Why?
| | Colorado | 19 | 2023 | 4092 | 0.980 |
Why?
| | Male | 68 | 2023 | 55418 | 0.950 |
Why?
| | Industry | 4 | 2019 | 65 | 0.920 |
Why?
| | Dehydration | 3 | 2020 | 40 | 0.870 |
Why?
| | Air Pollutants | 4 | 2020 | 244 | 0.870 |
Why?
| | Environmental Monitoring | 5 | 2022 | 255 | 0.840 |
Why?
| | Occupational Stress | 1 | 2023 | 35 | 0.820 |
Why?
| | Point-of-Care Testing | 2 | 2023 | 29 | 0.810 |
Why?
| | Middle Aged | 50 | 2021 | 26620 | 0.810 |
Why?
| | Longitudinal Studies | 10 | 2021 | 2388 | 0.810 |
Why?
| | Acute Kidney Injury | 2 | 2019 | 637 | 0.800 |
Why?
| | Analgesics, Opioid | 2 | 2018 | 771 | 0.750 |
Why?
| | Efficiency | 2 | 2018 | 84 | 0.730 |
Why?
| | Risk Factors | 23 | 2021 | 8612 | 0.720 |
Why?
| | Arsenic | 1 | 2021 | 37 | 0.720 |
Why?
| | Cross-Sectional Studies | 12 | 2021 | 4404 | 0.700 |
Why?
| | Anemia | 1 | 2021 | 143 | 0.700 |
Why?
| | Neurophysins | 1 | 2020 | 5 | 0.690 |
Why?
| | Capacity Building | 1 | 2020 | 51 | 0.680 |
Why?
| | Tobacco Smoke Pollution | 2 | 2021 | 217 | 0.680 |
Why?
| | Sleep | 2 | 2023 | 631 | 0.680 |
Why?
| | Biomarkers | 6 | 2020 | 3397 | 0.670 |
Why?
| | Glycopeptides | 1 | 2020 | 43 | 0.670 |
Why?
| | Vasopressins | 1 | 2020 | 56 | 0.670 |
Why?
| | Inhalation Exposure | 1 | 2020 | 96 | 0.670 |
Why?
| | Respiratory Hypersensitivity | 4 | 2004 | 60 | 0.660 |
Why?
| | HLA-DP Antigens | 6 | 2011 | 32 | 0.660 |
Why?
| | Protein Precursors | 1 | 2020 | 119 | 0.650 |
Why?
| | Cell Proliferation | 5 | 2018 | 2173 | 0.630 |
Why?
| | Presenteeism | 1 | 2018 | 5 | 0.620 |
Why?
| | Female | 57 | 2021 | 59347 | 0.620 |
Why?
| | Smoking | 8 | 2021 | 1382 | 0.620 |
Why?
| | Veterinarians | 1 | 2018 | 11 | 0.610 |
Why?
| | Young Adult | 13 | 2021 | 10458 | 0.600 |
Why?
| | Body Composition | 1 | 2021 | 590 | 0.590 |
Why?
| | Drug Utilization | 1 | 2018 | 164 | 0.580 |
Why?
| | Accidents, Occupational | 2 | 2015 | 14 | 0.580 |
Why?
| | Text Messaging | 1 | 2020 | 152 | 0.580 |
Why?
| | CD4-Positive T-Lymphocytes | 12 | 2011 | 960 | 0.570 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 86 | 0.560 |
Why?
| | Environmental Exposure | 8 | 2013 | 372 | 0.560 |
Why?
| | Metabolic Diseases | 1 | 2018 | 98 | 0.560 |
Why?
| | Extraction and Processing Industry | 2 | 2014 | 11 | 0.560 |
Why?
| | Professional Role | 1 | 2018 | 148 | 0.560 |
Why?
| | Work Performance | 1 | 2017 | 6 | 0.560 |
Why?
| | Guidelines as Topic | 1 | 2018 | 241 | 0.540 |
Why?
| | Renal Insufficiency | 1 | 2018 | 137 | 0.540 |
Why?
| | Mass Screening | 3 | 2022 | 979 | 0.540 |
Why?
| | Lymphocyte Activation | 16 | 2014 | 1036 | 0.530 |
Why?
| | Health Policy | 1 | 2019 | 330 | 0.530 |
Why?
| | Sarcoidosis, Pulmonary | 8 | 2010 | 58 | 0.520 |
Why?
| | Federal Government | 1 | 2016 | 26 | 0.510 |
Why?
| | CpG Islands | 1 | 2015 | 118 | 0.500 |
Why?
| | Antigens, Bacterial | 4 | 2012 | 111 | 0.490 |
Why?
| | Food Industry | 1 | 2015 | 14 | 0.490 |
Why?
| | Safety | 2 | 2015 | 298 | 0.490 |
Why?
| | Chronic Pain | 1 | 2018 | 208 | 0.490 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2015 | 1128 | 0.480 |
Why?
| | Guideline Adherence | 1 | 2018 | 489 | 0.470 |
Why?
| | United States | 16 | 2022 | 12144 | 0.460 |
Why?
| | Occupational Health Services | 1 | 2014 | 31 | 0.450 |
Why?
| | Population Surveillance | 3 | 2018 | 385 | 0.440 |
Why?
| | Oil and Gas Fields | 1 | 2014 | 32 | 0.440 |
Why?
| | Lung | 11 | 2019 | 3521 | 0.440 |
Why?
| | Natural Gas | 4 | 2014 | 29 | 0.420 |
Why?
| | Granuloma, Respiratory Tract | 4 | 2007 | 12 | 0.420 |
Why?
| | Life Style | 1 | 2015 | 428 | 0.400 |
Why?
| | Aged | 22 | 2021 | 18973 | 0.400 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 200 | 0.400 |
Why?
| | Influenza, Human | 2 | 2022 | 543 | 0.400 |
Why?
| | Hypertension | 1 | 2020 | 1052 | 0.390 |
Why?
| | DNA Methylation | 1 | 2015 | 493 | 0.380 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 413 | 0.380 |
Why?
| | Mycobacterium | 3 | 2009 | 103 | 0.380 |
Why?
| | Latin America | 2 | 2022 | 68 | 0.380 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1131 | 0.370 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 544 | 0.370 |
Why?
| | Mass Spectrometry | 1 | 2014 | 622 | 0.370 |
Why?
| | Logistic Models | 7 | 2022 | 1830 | 0.360 |
Why?
| | Air Pollution, Indoor | 3 | 2019 | 108 | 0.360 |
Why?
| | Mental Disorders | 1 | 2018 | 889 | 0.350 |
Why?
| | Macrophages | 2 | 2015 | 1259 | 0.350 |
Why?
| | Mycobacterium Infections | 2 | 2012 | 61 | 0.350 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1175 | 0.350 |
Why?
| | HLA-DP beta-Chains | 7 | 2014 | 76 | 0.350 |
Why?
| | Macrophages, Alveolar | 2 | 2004 | 348 | 0.340 |
Why?
| | Ferritins | 2 | 2014 | 52 | 0.340 |
Why?
| | Prevalence | 3 | 2021 | 2248 | 0.340 |
Why?
| | Electrolytes | 2 | 2020 | 55 | 0.340 |
Why?
| | Health Status | 3 | 2021 | 717 | 0.330 |
Why?
| | B-Lymphocytes | 1 | 2014 | 763 | 0.320 |
Why?
| | Temperature | 2 | 2023 | 564 | 0.320 |
Why?
| | Perception | 3 | 2021 | 309 | 0.320 |
Why?
| | Delivery of Health Care | 1 | 2016 | 828 | 0.320 |
Why?
| | Data Collection | 1 | 2011 | 618 | 0.310 |
Why?
| | T-Lymphocytes | 3 | 2014 | 1735 | 0.310 |
Why?
| | HLA Antigens | 4 | 2010 | 220 | 0.310 |
Why?
| | Multivariate Analysis | 6 | 2018 | 1422 | 0.310 |
Why?
| | Pulmonary Fibrosis | 2 | 2005 | 321 | 0.300 |
Why?
| | HLA-DR Antigens | 7 | 2010 | 219 | 0.300 |
Why?
| | Insurance Claim Reporting | 2 | 2018 | 21 | 0.290 |
Why?
| | Genetic Predisposition to Disease | 8 | 2010 | 2090 | 0.290 |
Why?
| | Police | 1 | 2007 | 30 | 0.290 |
Why?
| | Program Development | 2 | 2020 | 339 | 0.280 |
Why?
| | Internet | 1 | 2011 | 591 | 0.280 |
Why?
| | Prospective Studies | 5 | 2020 | 6198 | 0.280 |
Why?
| | Immunization | 3 | 2005 | 397 | 0.280 |
Why?
| | Methamphetamine | 1 | 2007 | 51 | 0.280 |
Why?
| | Sensitivity and Specificity | 7 | 2023 | 1690 | 0.280 |
Why?
| | Case-Control Studies | 10 | 2018 | 3007 | 0.280 |
Why?
| | Respiratory Protective Devices | 2 | 2007 | 11 | 0.280 |
Why?
| | Wyoming | 2 | 2018 | 17 | 0.270 |
Why?
| | Apoptosis | 4 | 2005 | 2349 | 0.270 |
Why?
| | Pilot Projects | 2 | 2021 | 1361 | 0.260 |
Why?
| | Cohort Studies | 6 | 2019 | 4884 | 0.260 |
Why?
| | Central Nervous System Stimulants | 1 | 2007 | 140 | 0.260 |
Why?
| | Proteomics | 2 | 2011 | 815 | 0.260 |
Why?
| | Spectrometry, Mass, Secondary Ion | 1 | 2005 | 1 | 0.260 |
Why?
| | Plutonium | 1 | 2005 | 2 | 0.250 |
Why?
| | Neopterin | 2 | 2003 | 9 | 0.250 |
Why?
| | Chemical Industry | 1 | 2005 | 9 | 0.250 |
Why?
| | Particulate Matter | 2 | 2020 | 185 | 0.240 |
Why?
| | Antigen Presentation | 4 | 2014 | 188 | 0.240 |
Why?
| | Research | 3 | 2018 | 389 | 0.240 |
Why?
| | Bronchoalveolar Lavage Fluid | 8 | 2009 | 580 | 0.240 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2006 | 70 | 0.240 |
Why?
| | Electronic Health Records | 1 | 2011 | 801 | 0.240 |
Why?
| | Pandemics | 3 | 2022 | 1311 | 0.240 |
Why?
| | Nuclear Warfare | 1 | 2004 | 6 | 0.240 |
Why?
| | Research Design | 2 | 2022 | 919 | 0.230 |
Why?
| | Cadmium | 2 | 2022 | 58 | 0.230 |
Why?
| | Age of Onset | 1 | 2006 | 444 | 0.230 |
Why?
| | Risk Assessment | 5 | 2021 | 2958 | 0.220 |
Why?
| | Residence Characteristics | 2 | 2018 | 274 | 0.220 |
Why?
| | Vaccination | 1 | 2011 | 1202 | 0.220 |
Why?
| | Climate Change | 2 | 2022 | 118 | 0.210 |
Why?
| | Pneumoconiosis | 2 | 2004 | 12 | 0.210 |
Why?
| | Prognosis | 5 | 2020 | 3315 | 0.210 |
Why?
| | Inflammation Mediators | 3 | 2014 | 475 | 0.210 |
Why?
| | Volcanic Eruptions | 1 | 2022 | 6 | 0.200 |
Why?
| | Ventilation | 2 | 2019 | 31 | 0.200 |
Why?
| | Metals, Heavy | 1 | 2022 | 19 | 0.200 |
Why?
| | Respiratory Function Tests | 5 | 2019 | 522 | 0.200 |
Why?
| | Metals | 2 | 2004 | 105 | 0.200 |
Why?
| | Immunity, Active | 1 | 2002 | 9 | 0.200 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 350 | 0.200 |
Why?
| | Health Surveys | 2 | 2018 | 441 | 0.200 |
Why?
| | Crops, Agricultural | 2 | 2019 | 28 | 0.200 |
Why?
| | Aged, 80 and over | 8 | 2011 | 6307 | 0.200 |
Why?
| | Respiratory Tract Infections | 1 | 2006 | 320 | 0.190 |
Why?
| | Models, Immunological | 1 | 2002 | 90 | 0.190 |
Why?
| | Calculi | 1 | 2021 | 16 | 0.190 |
Why?
| | Organizational Innovation | 1 | 2022 | 132 | 0.180 |
Why?
| | Cotinine | 1 | 2021 | 69 | 0.180 |
Why?
| | Time Factors | 4 | 2019 | 6077 | 0.180 |
Why?
| | Nickel | 1 | 2021 | 50 | 0.180 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1310 | 0.180 |
Why?
| | Virus Diseases | 1 | 2022 | 195 | 0.170 |
Why?
| | Beverages | 1 | 2020 | 60 | 0.170 |
Why?
| | Policy | 1 | 2021 | 137 | 0.170 |
Why?
| | Noise, Occupational | 1 | 2019 | 5 | 0.170 |
Why?
| | Adolescent | 7 | 2021 | 17811 | 0.170 |
Why?
| | Kidney Function Tests | 1 | 2020 | 140 | 0.170 |
Why?
| | HLA-DQ Antigens | 4 | 2010 | 174 | 0.160 |
Why?
| | Hemoglobins | 1 | 2021 | 308 | 0.160 |
Why?
| | Social Support | 1 | 2023 | 531 | 0.160 |
Why?
| | Sri Lanka | 1 | 2019 | 7 | 0.160 |
Why?
| | Global Health | 2 | 2016 | 287 | 0.160 |
Why?
| | Specific Gravity | 1 | 2019 | 11 | 0.160 |
Why?
| | Central America | 1 | 2019 | 16 | 0.160 |
Why?
| | Nutritional Status | 1 | 2021 | 286 | 0.160 |
Why?
| | Body Mass Index | 2 | 2018 | 1957 | 0.160 |
Why?
| | Heat-Shock Response | 1 | 2019 | 46 | 0.160 |
Why?
| | Lung Diseases, Interstitial | 1 | 2004 | 495 | 0.160 |
Why?
| | Neoplasms | 3 | 2018 | 2088 | 0.160 |
Why?
| | India | 1 | 2019 | 134 | 0.160 |
Why?
| | Blood Proteins | 2 | 2011 | 222 | 0.160 |
Why?
| | Climate | 1 | 2019 | 79 | 0.160 |
Why?
| | Interferon-gamma | 5 | 2015 | 719 | 0.160 |
Why?
| | Unemployment | 1 | 2018 | 39 | 0.150 |
Why?
| | Headache Disorders | 1 | 2018 | 12 | 0.150 |
Why?
| | Work Capacity Evaluation | 1 | 2018 | 11 | 0.150 |
Why?
| | Digestive System Diseases | 1 | 2018 | 23 | 0.150 |
Why?
| | False Positive Reactions | 1 | 2018 | 109 | 0.150 |
Why?
| | Granuloma | 2 | 2014 | 82 | 0.150 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2006 | 907 | 0.150 |
Why?
| | Survivorship | 1 | 2018 | 41 | 0.150 |
Why?
| | Musculoskeletal Pain | 1 | 2018 | 23 | 0.150 |
Why?
| | Urologic Diseases | 1 | 2018 | 35 | 0.150 |
Why?
| | Educational Status | 1 | 2020 | 408 | 0.150 |
Why?
| | Models, Psychological | 1 | 2020 | 297 | 0.150 |
Why?
| | Asbestosis | 2 | 2011 | 12 | 0.150 |
Why?
| | Job Satisfaction | 1 | 2020 | 168 | 0.150 |
Why?
| | Adaptation, Physiological | 1 | 2022 | 484 | 0.150 |
Why?
| | Cytokines | 3 | 2014 | 1824 | 0.150 |
Why?
| | Reference Standards | 1 | 2018 | 159 | 0.150 |
Why?
| | Benchmarking | 1 | 2019 | 162 | 0.150 |
Why?
| | Fever | 1 | 2019 | 280 | 0.150 |
Why?
| | Catalase | 2 | 2009 | 118 | 0.150 |
Why?
| | Self Report | 1 | 2021 | 695 | 0.150 |
Why?
| | Physical Exertion | 1 | 2019 | 209 | 0.140 |
Why?
| | Awareness | 1 | 2018 | 93 | 0.140 |
Why?
| | Antibodies, Monoclonal | 3 | 2012 | 1257 | 0.140 |
Why?
| | Epidemics | 1 | 2018 | 66 | 0.140 |
Why?
| | Arthritis | 1 | 2018 | 109 | 0.140 |
Why?
| | Employment | 1 | 2018 | 137 | 0.140 |
Why?
| | Air Pollutants, Occupational | 3 | 2007 | 27 | 0.140 |
Why?
| | Respiratory Tract Diseases | 1 | 2018 | 139 | 0.140 |
Why?
| | Mice | 8 | 2019 | 14847 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2018 | 237 | 0.130 |
Why?
| | Diagnosis, Differential | 4 | 2004 | 1331 | 0.130 |
Why?
| | Immunity, Innate | 1 | 2002 | 720 | 0.130 |
Why?
| | Nuclear Energy | 1 | 2016 | 2 | 0.130 |
Why?
| | Nuclear Power Plants | 1 | 2016 | 2 | 0.130 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1078 | 0.130 |
Why?
| | Community Health Planning | 1 | 2016 | 42 | 0.130 |
Why?
| | HLA-DRB1 Chains | 6 | 2010 | 97 | 0.130 |
Why?
| | Public-Private Sector Partnerships | 1 | 2016 | 43 | 0.130 |
Why?
| | Motivation | 1 | 2020 | 488 | 0.130 |
Why?
| | Kidney Diseases | 1 | 2019 | 349 | 0.130 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1996 | 82 | 0.130 |
Why?
| | Linear Models | 1 | 2018 | 768 | 0.130 |
Why?
| | Cell Line | 2 | 2015 | 2629 | 0.130 |
Why?
| | Population Health | 1 | 2016 | 42 | 0.130 |
Why?
| | Hypersensitivity | 2 | 2012 | 252 | 0.120 |
Why?
| | Recurrence | 1 | 2018 | 925 | 0.120 |
Why?
| | Cell Line, Transformed | 2 | 2014 | 133 | 0.120 |
Why?
| | Mast Cells | 1 | 1996 | 117 | 0.120 |
Why?
| | Radiography, Thoracic | 4 | 2006 | 150 | 0.120 |
Why?
| | Retrospective Studies | 4 | 2020 | 12521 | 0.120 |
Why?
| | Disease Progression | 5 | 2011 | 2371 | 0.120 |
Why?
| | Heart Diseases | 1 | 2018 | 329 | 0.120 |
Why?
| | Medical Laboratory Personnel | 2 | 2006 | 7 | 0.120 |
Why?
| | Communication | 1 | 2020 | 733 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2018 | 207 | 0.120 |
Why?
| | Macrophage Activation | 1 | 2015 | 163 | 0.120 |
Why?
| | Community Health Services | 1 | 2016 | 212 | 0.120 |
Why?
| | Program Evaluation | 1 | 2018 | 820 | 0.110 |
Why?
| | Research Personnel | 1 | 2016 | 147 | 0.110 |
Why?
| | Ions | 1 | 2014 | 59 | 0.110 |
Why?
| | Fruit | 1 | 2015 | 119 | 0.110 |
Why?
| | Models, Biological | 1 | 2021 | 1611 | 0.110 |
Why?
| | Vegetables | 1 | 2015 | 133 | 0.110 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2011 | 134 | 0.110 |
Why?
| | Endotoxins | 2 | 2006 | 211 | 0.110 |
Why?
| | Incidence | 2 | 2018 | 2314 | 0.110 |
Why?
| | Allergens | 3 | 2006 | 410 | 0.110 |
Why?
| | Health Impact Assessment | 1 | 2013 | 7 | 0.110 |
Why?
| | Genotype | 6 | 2011 | 1757 | 0.110 |
Why?
| | Sex Factors | 1 | 2018 | 1707 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 898 | 0.100 |
Why?
| | Water Supply | 2 | 2016 | 67 | 0.100 |
Why?
| | Bacterial Proteins | 2 | 2009 | 735 | 0.100 |
Why?
| | Immunologic Memory | 2 | 2005 | 313 | 0.100 |
Why?
| | Cell Division | 2 | 2004 | 754 | 0.100 |
Why?
| | Maximum Allowable Concentration | 2 | 2019 | 14 | 0.100 |
Why?
| | Up-Regulation | 2 | 2006 | 802 | 0.100 |
Why?
| | Antigens, Fungal | 1 | 2012 | 23 | 0.100 |
Why?
| | Hydrocarbons | 1 | 2012 | 29 | 0.100 |
Why?
| | Paper | 1 | 2011 | 8 | 0.100 |
Why?
| | Personnel, Hospital | 1 | 2011 | 24 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 2 | 2005 | 383 | 0.090 |
Why?
| | Vital Capacity | 2 | 2019 | 254 | 0.090 |
Why?
| | Health Services Research | 1 | 2014 | 373 | 0.090 |
Why?
| | Glutamic Acid | 2 | 2003 | 210 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1381 | 0.090 |
Why?
| | Pulmonary Gas Exchange | 2 | 2004 | 117 | 0.090 |
Why?
| | Alleles | 4 | 2011 | 789 | 0.090 |
Why?
| | Forced Expiratory Volume | 2 | 2019 | 471 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2322 | 0.090 |
Why?
| | Phenotype | 3 | 2010 | 2784 | 0.090 |
Why?
| | Schools, Veterinary | 1 | 2010 | 2 | 0.090 |
Why?
| | Genes, MHC Class II | 1 | 2010 | 69 | 0.090 |
Why?
| | Substance-Related Disorders | 1 | 2018 | 942 | 0.090 |
Why?
| | Sulfasalazine | 1 | 2009 | 21 | 0.080 |
Why?
| | Mesalamine | 1 | 2009 | 8 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 296 | 0.080 |
Why?
| | Animals | 9 | 2019 | 31570 | 0.080 |
Why?
| | Air Pollution | 1 | 2012 | 169 | 0.080 |
Why?
| | Uveitis | 1 | 2010 | 115 | 0.080 |
Why?
| | Cell Separation | 2 | 2009 | 290 | 0.080 |
Why?
| | Silicosis | 1 | 1989 | 22 | 0.080 |
Why?
| | Alcohol Drinking | 1 | 2015 | 655 | 0.080 |
Why?
| | Latent Tuberculosis | 1 | 2009 | 64 | 0.080 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2004 | 615 | 0.080 |
Why?
| | RNA, Messenger | 2 | 2006 | 2550 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2273 | 0.070 |
Why?
| | Swimming Pools | 1 | 2007 | 5 | 0.070 |
Why?
| | Hydrotherapy | 1 | 2007 | 8 | 0.070 |
Why?
| | Severity of Illness Index | 4 | 2007 | 2540 | 0.070 |
Why?
| | Crime | 1 | 2007 | 58 | 0.070 |
Why?
| | Spirometry | 3 | 2019 | 223 | 0.070 |
Why?
| | Animal Technicians | 2 | 2006 | 3 | 0.070 |
Why?
| | Water Microbiology | 1 | 2007 | 78 | 0.070 |
Why?
| | Influenza Vaccines | 1 | 2011 | 497 | 0.070 |
Why?
| | Cells, Cultured | 5 | 2009 | 3862 | 0.070 |
Why?
| | Aerosols | 1 | 2007 | 150 | 0.070 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2007 | 153 | 0.070 |
Why?
| | Reactive Oxygen Species | 2 | 2008 | 522 | 0.070 |
Why?
| | Transcription Factor AP-1 | 1 | 2006 | 81 | 0.070 |
Why?
| | Genetic Markers | 2 | 2010 | 320 | 0.070 |
Why?
| | Gene Dosage | 1 | 2006 | 129 | 0.060 |
Why?
| | Risk | 2 | 2007 | 810 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 641 | 0.060 |
Why?
| | Polymorphism, Genetic | 2 | 2010 | 610 | 0.060 |
Why?
| | RNA Precursors | 1 | 2006 | 135 | 0.060 |
Why?
| | Biopsy | 2 | 2005 | 1024 | 0.060 |
Why?
| | Chromosomes, Human, X | 1 | 2005 | 61 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 2 | 2006 | 489 | 0.060 |
Why?
| | Biomarkers, Tumor | 1 | 2011 | 1032 | 0.060 |
Why?
| | Psychological Tests | 1 | 2005 | 120 | 0.060 |
Why?
| | Radioisotopes | 1 | 2004 | 28 | 0.060 |
Why?
| | Exercise | 1 | 2015 | 1641 | 0.060 |
Why?
| | Treatment Outcome | 3 | 2014 | 9050 | 0.060 |
Why?
| | Genetic Linkage | 1 | 2005 | 294 | 0.060 |
Why?
| | Radiation Dosage | 1 | 2005 | 133 | 0.060 |
Why?
| | Antioxidants | 1 | 2008 | 529 | 0.060 |
Why?
| | HLA-DRB3 Chains | 1 | 2003 | 2 | 0.060 |
Why?
| | HLA-DRB5 Chains | 1 | 2003 | 2 | 0.060 |
Why?
| | fas Receptor | 1 | 2004 | 91 | 0.060 |
Why?
| | HLA-DRB4 Chains | 1 | 2003 | 6 | 0.060 |
Why?
| | Odds Ratio | 3 | 2014 | 951 | 0.060 |
Why?
| | Public Health | 2 | 2022 | 435 | 0.060 |
Why?
| | Phagocytes | 1 | 2004 | 90 | 0.060 |
Why?
| | Tuberculosis | 1 | 2006 | 241 | 0.060 |
Why?
| | HLA-DQ beta-Chains | 1 | 2003 | 57 | 0.050 |
Why?
| | CD28 Antigens | 1 | 2003 | 47 | 0.050 |
Why?
| | Chi-Square Distribution | 1 | 2004 | 492 | 0.050 |
Why?
| | Animals, Laboratory | 1 | 2003 | 13 | 0.050 |
Why?
| | Lipopolysaccharides | 1 | 2006 | 813 | 0.050 |
Why?
| | Immunologic Tests | 1 | 2003 | 16 | 0.050 |
Why?
| | Kinetics | 1 | 2006 | 1547 | 0.050 |
Why?
| | Physiological Phenomena | 1 | 2002 | 1 | 0.050 |
Why?
| | NF-kappa B | 1 | 2006 | 636 | 0.050 |
Why?
| | Disposable Equipment | 1 | 2002 | 15 | 0.050 |
Why?
| | Genetic Variation | 1 | 2007 | 868 | 0.050 |
Why?
| | Contraindications | 1 | 2002 | 84 | 0.050 |
Why?
| | In Situ Nick-End Labeling | 1 | 2002 | 119 | 0.050 |
Why?
| | Nuclear Proteins | 1 | 2006 | 591 | 0.050 |
Why?
| | Patch Tests | 1 | 2002 | 51 | 0.050 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2002 | 81 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2004 | 587 | 0.050 |
Why?
| | Epitopes | 1 | 2003 | 434 | 0.050 |
Why?
| | Point-of-Care Systems | 1 | 2023 | 130 | 0.050 |
Why?
| | Nuclear Weapons | 2 | 2011 | 5 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 787 | 0.050 |
Why?
| | Radiography | 1 | 2003 | 803 | 0.040 |
Why?
| | Equipment Design | 1 | 2002 | 503 | 0.040 |
Why?
| | Exercise Test | 1 | 2003 | 547 | 0.040 |
Why?
| | ROC Curve | 2 | 2003 | 441 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 1837 | 0.040 |
Why?
| | 2,4-Dinitrophenol | 1 | 2019 | 8 | 0.040 |
Why?
| | Kidney Medulla | 1 | 2019 | 29 | 0.040 |
Why?
| | Hearing Loss, Noise-Induced | 1 | 2019 | 21 | 0.040 |
Why?
| | Amino Acid Sequence | 4 | 2009 | 1981 | 0.040 |
Why?
| | Quality of Life | 2 | 2012 | 2344 | 0.040 |
Why?
| | Infliximab | 2 | 2012 | 93 | 0.040 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2019 | 61 | 0.040 |
Why?
| | Acute Disease | 1 | 2002 | 909 | 0.040 |
Why?
| | Molecular Sequence Data | 4 | 2009 | 2783 | 0.040 |
Why?
| | Transcription Factors | 1 | 2006 | 1526 | 0.040 |
Why?
| | Selection Bias | 1 | 2018 | 33 | 0.040 |
Why?
| | Organizational Case Studies | 1 | 2018 | 68 | 0.040 |
Why?
| | Cities | 1 | 2018 | 80 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2011 | 2159 | 0.040 |
Why?
| | Health | 1 | 2018 | 74 | 0.040 |
Why?
| | Genetic Association Studies | 2 | 2010 | 339 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 990 | 0.040 |
Why?
| | Fibrosis | 1 | 2000 | 452 | 0.040 |
Why?
| | Haplotypes | 2 | 2010 | 448 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2018 | 193 | 0.030 |
Why?
| | Cost of Illness | 1 | 2018 | 255 | 0.030 |
Why?
| | Histocompatibility Testing | 2 | 2009 | 115 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 725 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2021 | 4392 | 0.030 |
Why?
| | Observer Variation | 1 | 1997 | 298 | 0.030 |
Why?
| | Poverty | 1 | 2019 | 440 | 0.030 |
Why?
| | Gene Frequency | 2 | 2010 | 476 | 0.030 |
Why?
| | Community Health Nursing | 1 | 2016 | 57 | 0.030 |
Why?
| | Sanitation | 1 | 2016 | 49 | 0.030 |
Why?
| | Antibody Formation | 1 | 1997 | 266 | 0.030 |
Why?
| | Double-Blind Method | 2 | 2012 | 1656 | 0.030 |
Why?
| | Antigens | 1 | 1997 | 317 | 0.030 |
Why?
| | Community Participation | 1 | 2016 | 112 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 3 | 2002 | 310 | 0.030 |
Why?
| | Education, Nursing | 1 | 2016 | 78 | 0.030 |
Why?
| | Siblings | 2 | 2006 | 220 | 0.030 |
Why?
| | Asthma | 2 | 2019 | 2021 | 0.030 |
Why?
| | Mitochondria | 1 | 2019 | 744 | 0.030 |
Why?
| | Universities | 1 | 2016 | 339 | 0.030 |
Why?
| | Qualitative Research | 1 | 2018 | 924 | 0.030 |
Why?
| | Disease Susceptibility | 2 | 2000 | 316 | 0.030 |
Why?
| | Cleft Palate | 1 | 2014 | 49 | 0.030 |
Why?
| | Education, Medical | 1 | 2016 | 214 | 0.030 |
Why?
| | Neural Tube Defects | 1 | 2014 | 59 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 2014 | 124 | 0.030 |
Why?
| | Interleukin-2 | 2 | 2005 | 413 | 0.030 |
Why?
| | Lung Diseases | 1 | 1999 | 690 | 0.030 |
Why?
| | Dyspnea | 2 | 2005 | 212 | 0.030 |
Why?
| | Pregnancy | 2 | 2014 | 5503 | 0.030 |
Why?
| | Maternal Exposure | 1 | 2014 | 138 | 0.030 |
Why?
| | Politics | 1 | 2013 | 78 | 0.020 |
Why?
| | Pneumonia | 1 | 1997 | 563 | 0.020 |
Why?
| | Epidemiological Monitoring | 1 | 2012 | 46 | 0.020 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2011 | 34 | 0.020 |
Why?
| | Inflammation | 1 | 2002 | 2465 | 0.020 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2002 | 18 | 0.020 |
Why?
| | Finland | 1 | 2011 | 69 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2012 | 247 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 396 | 0.020 |
Why?
| | Netherlands | 1 | 2010 | 64 | 0.020 |
Why?
| | Premature Birth | 1 | 2014 | 275 | 0.020 |
Why?
| | Hazardous Substances | 1 | 2010 | 9 | 0.020 |
Why?
| | Japan | 1 | 2010 | 85 | 0.020 |
Why?
| | Toxoplasma | 1 | 2010 | 31 | 0.020 |
Why?
| | United Kingdom | 1 | 2010 | 226 | 0.020 |
Why?
| | Salmonella enterica | 1 | 2010 | 51 | 0.020 |
Why?
| | HLA-A Antigens | 1 | 1989 | 49 | 0.020 |
Why?
| | Predictive Value of Tests | 2 | 2005 | 1791 | 0.020 |
Why?
| | Antigen-Presenting Cells | 1 | 2009 | 150 | 0.020 |
Why?
| | HLA-B Antigens | 1 | 1989 | 56 | 0.020 |
Why?
| | Demography | 1 | 2009 | 258 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2018 | 1875 | 0.020 |
Why?
| | Halogens | 1 | 2007 | 13 | 0.020 |
Why?
| | Heart Defects, Congenital | 1 | 2014 | 683 | 0.020 |
Why?
| | Codon | 1 | 2007 | 85 | 0.020 |
Why?
| | Tuberculin | 1 | 2006 | 6 | 0.020 |
Why?
| | Decision Making | 1 | 2013 | 760 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2009 | 295 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1014 | 0.020 |
Why?
| | Disinfection | 1 | 2007 | 107 | 0.020 |
Why?
| | Placebos | 1 | 2006 | 197 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 288 | 0.020 |
Why?
| | Eye | 1 | 2006 | 97 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2007 | 452 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2009 | 1075 | 0.020 |
Why?
| | Caspase 8 | 1 | 2005 | 43 | 0.020 |
Why?
| | Genetic Techniques | 1 | 2005 | 57 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2005 | 132 | 0.020 |
Why?
| | Free Radical Scavengers | 1 | 2005 | 78 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 363 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2011 | 787 | 0.010 |
Why?
| | Metalloporphyrins | 1 | 2005 | 103 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2010 | 1176 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2005 | 486 | 0.010 |
Why?
| | Caspases | 1 | 2005 | 243 | 0.010 |
Why?
| | Species Specificity | 1 | 2005 | 541 | 0.010 |
Why?
| | Abatacept | 1 | 2003 | 40 | 0.010 |
Why?
| | Mycobacterium tuberculosis | 1 | 2006 | 269 | 0.010 |
Why?
| | Radioallergosorbent Test | 1 | 2003 | 3 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2014 | 5038 | 0.010 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2003 | 74 | 0.010 |
Why?
| | Thymidine | 1 | 2003 | 58 | 0.010 |
Why?
| | Geography | 1 | 2003 | 176 | 0.010 |
Why?
| | Skin Tests | 1 | 2003 | 116 | 0.010 |
Why?
| | Genetic Testing | 1 | 2005 | 381 | 0.010 |
Why?
| | Immunoconjugates | 1 | 2003 | 87 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2003 | 291 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2008 | 1068 | 0.010 |
Why?
| | Autoantibodies | 1 | 1989 | 1350 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 180 | 0.010 |
Why?
| | Mice, Inbred A | 1 | 2001 | 45 | 0.010 |
Why?
| | Ceramics | 1 | 2001 | 16 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 242 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2001 | 323 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2001 | 353 | 0.010 |
Why?
| | Dogs | 1 | 2001 | 331 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 11 | 0.010 |
Why?
| | Forecasting | 1 | 2001 | 331 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1999 | 25 | 0.010 |
Why?
| | Models, Animal | 1 | 2001 | 340 | 0.010 |
Why?
| | Models, Statistical | 1 | 2003 | 595 | 0.010 |
Why?
| | Clone Cells | 1 | 1999 | 247 | 0.010 |
Why?
| | Liver | 1 | 2006 | 1633 | 0.010 |
Why?
| | Cell Movement | 1 | 2002 | 863 | 0.010 |
Why?
| | Skin | 1 | 2002 | 653 | 0.010 |
Why?
| | Depression | 1 | 2005 | 1133 | 0.010 |
Why?
| | Models, Molecular | 1 | 2001 | 1368 | 0.010 |
Why?
| | Bronchography | 1 | 1993 | 9 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2005 | 4598 | 0.010 |
Why?
| | Bronchiectasis | 1 | 1993 | 106 | 0.010 |
Why?
|
|
Newman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|